(Total Views: 341)
Posted On: 02/11/2019 7:08:48 PM
Post# of 72446
Here is another Kevetrin deal comparison:
https://www.fiercebiotech.com/biotech/harpoon...r-platform
Harpoon Therapeutics
$340M market cap. (they recently raised about $70 million cash)
HPN424 Prostate cancer - Conducting phase 1 (Started in 2018)
3 other preclinical indications at this time
$17 million upfront with $600 million in milestones for a preclinical CAR-T system. Now, only in the middle of phase 1, the company is worth more than $250 million beyond their cash holdings.
A $24 million market cap for IPIX is the result of many missed targets, an extensive smear campaign, OTC exchange, and severe balance sheet issues. Even a small deal can correct us upward in a big way.
https://www.fiercebiotech.com/biotech/harpoon...r-platform
Harpoon Therapeutics
$340M market cap. (they recently raised about $70 million cash)
HPN424 Prostate cancer - Conducting phase 1 (Started in 2018)
3 other preclinical indications at this time
Quote:
Harpoon previously signed a discovery and licensing deal with AbbVie in October 2017, granting the Big Pharma worldwide rights to develop and commercialize its TriTAC technology together with soluble T cell receptors. The deal included $17 million upfront, plus up to $600 million in potential milestone payments.
$17 million upfront with $600 million in milestones for a preclinical CAR-T system. Now, only in the middle of phase 1, the company is worth more than $250 million beyond their cash holdings.
A $24 million market cap for IPIX is the result of many missed targets, an extensive smear campaign, OTC exchange, and severe balance sheet issues. Even a small deal can correct us upward in a big way.
(0)
(0)
